Synmosa Biopharma Corporation (4114) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Synmosa Biopharma Corporation (4114:TWSE), powered by AI.

Current Price
$29.05
Sector
Healthcare
What is the Synmosa Biopharma Corporation stock price forecast?

Synmosa Biopharma Corporation is currently trading at $29.05. View real-time AI analysis on Alpha Lenz.

What is Synmosa Biopharma Corporation insider trading activity?

View the latest insider trading data for Synmosa Biopharma Corporation on Alpha Lenz.

What is Synmosa Biopharma Corporation's P/E ratio?

View Synmosa Biopharma Corporation's valuation metrics on Alpha Lenz.

Synmosa Biopharma Corporation

TWSE · 4114
NT$29.05-0.20(-0.68%)
Ask about Synmosa Biopharma Corporation's future dividend policy...
Alpha Chat Insight

Synmosa Biopharma Corporation's ROE is 10.3%. Explore profitability and growth together.

Ask for details

Company Overview

Synmosa Biopharma Corporation is a specialty pharmaceutical company headquartered in Taiwan, recognized for its comprehensive involvement in the healthcare sector. The company specializes in the research, development, manufacturing, and distribution of a wide array of pharmaceutical products, including prescription medicines, over-the-counter drugs, active pharmaceutical ingredients, medical devices, cosmetics, and chemical food additives. It plays a pivotal role in areas such as cardiovascular, respiratory, sex hormones, urology, and oncology therapies, providing essential solutions for both acute and chronic conditions. Synmosa also manufactures and markets environmental drugs and health-related products, supporting both human and animal health. Its product portfolio is built on advanced technology platforms including effervescent tablets, nasal sprays, metered dose inhalers, hormones, and granules, underlining its innovative capacity in drug delivery and formulation. With five GMP-certified manufacturing facilities and a strong footprint not only in Taiwan but also across markets in Asia, the Middle East, Africa, and Latin America, Synmosa Biopharma Corporation stands as one of the leading forces driving pharmaceutical standards and healthcare advancement in the region.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$6.19BRevenue
0.00Shares Out
0Employees

Margins

43.28%Gross
19.48%EBITDA
12.57%Operating
12.92%Pre-Tax
9.99%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

12.16%Rev 3Yr
15.29%Rev 5Yr
19.57%Op Inc 3Yr
45.45%Op Inc 5Yr
-0.02%Net Inc 3Yr
5.44%Net Inc 5Yr

Returns

4.70%ROA
10.29%ROE
6.56%ROIC

Financial Health

NT$1.89BCash & Cash Equivalents
NT$1.99BNet Debt
38.48%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Synmosa Biopharma Corporation (ticker: 4114) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic).

The current price is 29.05 with a P/E ratio of -x and P/B of -x.

ROE is 10.29% and operating margin is 12.57%. Annual revenue is $6.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Synmosa Biopharma Corporation (4114) Stock Forecast 2026 $29.05 — Price, Financials & Analyst Targets | Alpha Lenz